University of Canterbury, New Zealand.
University of Otago, New Zealand.
J Affect Disord. 2023 Oct 15;339:954-964. doi: 10.1016/j.jad.2023.05.077. Epub 2023 Jun 1.
Anxiety and depression are increasingly burdening society. We investigated whether micronutrients (vitamins and minerals), improve anxiety and depression symptoms in an adult community setting.
Participants (n = 150) describing functionally-impairing symptoms of anxiety/depression randomly received micronutrients or placebo for 10 weeks. Primary outcome measures were Patient Health Questionnaire-9 (PHQ-9), Generalised Anxiety Disorder Scale-7 (GAD-7), and Clinical Global Impression-Improvement scale (CGII). They were monitored online with regular phone contact with a clinical psychologist.
Linear mixed-effects modelling showed significant improvements in both groups, with the micronutrient group improving significantly more quickly on both the PHQ-9 (t = -2.17, p = 0.03) and the GAD-7 (t = -2.23, p = 0.03). Subsequent models with covariates showed that participant characteristics moderated time-by-group interactions; micronutrients provided fastest improvement relative to placebo for younger participants, those from lower socioeconomic groups and those who had previously tried psychiatric medication. On the CGII, there were no group differences at end-point ((F) = 1.36, p = 0.25, d = 0.19, 95 % CI [-0.13 to 0.51]), with 49 % of the micronutrient and 44 % of the placebo groups being identified responders. Participants on micronutrients had significantly increased bowel motions compared with placebo. There was no increased suicidal ideation, no serious adverse events and the blind was adequately maintained. Drop out was low at 8.7 %.
The improvement under placebo and lack of formal diagnoses limit generalizability.
Despite limited clinician contact, all participants improved significantly, though improvements were faster with micronutrients. Participants in some subgroups demonstrated a lower response to placebo, identifying where micronutrients may offer greatest potential as an intervention.
焦虑和抑郁日益成为社会负担。我们研究了在成人社区环境中,微量营养素(维生素和矿物质)是否能改善焦虑和抑郁症状。
描述有焦虑/抑郁功能障碍症状的参与者(n=150)随机接受微量营养素或安慰剂治疗 10 周。主要结局测量指标为患者健康问卷-9(PHQ-9)、广泛性焦虑障碍量表-7(GAD-7)和临床总体印象-改善量表(CGII)。他们通过定期与临床心理学家进行电话联系在线接受监测。
线性混合效应模型显示两组均有显著改善,微量营养素组在 PHQ-9(t=-2.17,p=0.03)和 GAD-7(t=-2.23,p=0.03)上的改善速度明显更快。随后的带有协变量的模型表明,参与者特征调节了时间与组间的相互作用;对于年轻参与者、来自社会经济地位较低群体的参与者以及之前尝试过精神科药物治疗的参与者,微量营养素相对于安慰剂提供了最快的改善。在 CGII 上,终点时无组间差异((F)=1.36,p=0.25,d=0.19,95%置信区间[-0.13 至 0.51]),微量营养素组和安慰剂组中有 49%和 44%的参与者被确定为有反应者。与安慰剂相比,服用微量营养素的参与者的排便次数明显增加。没有自杀意念增加,没有严重不良事件,盲法保持良好。脱落率为 8.7%。
安慰剂的改善和缺乏正式诊断限制了普遍性。
尽管与临床医生的接触有限,但所有参与者都有显著改善,尽管微量营养素组的改善速度更快。一些亚组的参与者对安慰剂的反应较低,这确定了微量营养素作为干预措施最有潜力的地方。